Table 2. Discrimination, calibration and net benefit metrics.

Cohort (n)	Discrimination AUC PCPTRC (%) (p-value for comparison to the AUC of PSA)	Calibration Risk range where PCPTRC primarily over-predicts Goodness of fit p-value	Net Benefit Range of PCPTRC risks of positive biopsy showing improved net benefit over the rules of biopsying everyone or no one (%)
ERSPC Goeteborg Round 1 (n=740)	72.0 (<.0001)	Entire range p < .0001	None
ERSPC Goeteborg Rounds 2-6 (n=1241)	56.2 (<.0001)	Entire range p < .0001	None
ERSPC Rotterdam Round 1 (n=2895)	70.0 (<.0001)	Entire range p <.0001	None
ERSPC Rotterdam Rounds 2-3 (n=1494)	61.0 (.15)	Entire range p <.0001	None
ERSPC Tarn (n=298)	66.7 (.07)	No over-prediction p <.0001	27-35
SABOR, US (n=392)	65.4 (.20)	No over-prediction p = 0.24	15-45
Cleveland Clinic, US (n=3286)	58.8 (<.0001)	50% and higher p < .0001	35-45
ProtecT, UK (n=7324)	63.9 (.14)	50% and lower p < .0001	30-85
Tyrol, Austria (n=5644)	66.7 (<.0001)	Entire range p < .0001	18-41
Durham VA, US (n=2419)	71.5 (<.0001)	No over-prediction p = .0008	25-100